Wire · operational-macro
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA has approved Lembaz (adrabetadex) injection, the first drug shown to reduce the risk of death and extend survival in patients with infantile-onset Niemann-Pick disease type C, a rare neurological lysosomal storage disorder. This treatment is suitable for patients weighing at least 7 kg with symptoms before age 6, providing a new therapeutic option where previous treatments did not reduce mortality.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now access the first approved drug that actually prolongs life for infantile Niemann-Pick disease patients. This approval opens a critical market for rare disease therapies with high unmet need and could accelerate similar drug development.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics